Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 13/20 | 0.36 |
| ▸ | RAF1 | P04049 | 10/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782735 | 0.83 | GSK3B (0.40) | — | |
| SCHEMBL22940330 | 0.78 | CRBN (0.36) | SRD5A1BRAFRAF1NPC1MAPK13 | |
| SCHEMBL10298268 | 0.78 | RAF1 (0.38) | BRAFRAF1NPC1MAPK13MAPK12 | |
| SCHEMBL10267990 | 0.78 | PDE3B (0.40) | BRAFRAF1CRBNEGFR | |
| SCHEMBL3009275 | 0.78 | DAO (0.37) | BRAFRAF1CRBN | |
| SCHEMBL30116209 | 0.78 | RAF1 (0.38) | BRAFRAF1NPC1MAPK13MAPK12 | |
| SCHEMBL16340476 | 0.76 | MB (0.39) | BRAFRAF1 | |
| SCHEMBL797188 | 0.75 | HTR2A (0.38) | BRAFRAF1EGFR | |
| SCHEMBL10199838 | 0.74 | HTR2A (0.37) | BRAFRAF1NPC1MAPK13MAPK12 | |
| SCHEMBL955098 | 0.74 | PDE3B (0.35) | BRAFRAF1CRBNEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049079-A1 | CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-02-19 | — | — | US | claimed |
| CN-116348465-A | Chiral synthesis of fused bicyclic RAF inhibitors | 爵士制药爱尔兰有限公司 | 2023-06-27 | — | — | CN | claimed |
| EP-4188923-A1 | CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2023-06-07 | — | — | EP | claimed |
| WO-2022023450-A1 | CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-02-03 | — | — | WO | claimed |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-04-02 | — | — | US | disclosed |
| US-20260049079-A1 | CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-02-19 | — | — | US | disclosed |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-05-20 | — | — | US | disclosed |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| US-20240124452-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2024-04-18 | — | — | US | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011146591-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011146591-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | SRD5A1 4528/4885BRAF 141/4885RAF1 93/4885 |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | SRD5A1 2437/4885BRAF 1/4885RAF1 2/4885 |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | SRD5A1 2437/4885BRAF 1/4885RAF1 2/4885 |
| US-20260049079-A1 | CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS | BRAF, HRAS, RAF1 | SRD5A1 2661/4885BRAF 1/4885RAF1 3/4885 |
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MAP4K5, MAP4K2, MAP4K1 | SRD5A1 2550/4885BRAF 959/4885RAF1 921/4885 |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | SRD5A1 1939/4885BRAF 3670/4885RAF1 3319/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | SRD5A1 833/4885BRAF 301/4885RAF1 369/4885 |
| US-20240124452-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, RAF1, NRAS | SRD5A1 2437/4885BRAF 1/4885RAF1 2/4885 |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, NRAS, RAF1 | SRD5A1 1526/4885BRAF 1/4885RAF1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.